A clinical study of Yiqi Huayu Jiedu decoction reducing the risk of postoperative gastric cancer recurrence and metastasis

Jiangsu Province Hospital of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) Patients with pathological diagnosis of gastric cancer;
•(2) Patients with histologically confirmed stage II, III after resection;
•(3) Patients with criteria of TCM syndrome of Qi deficiency of spleen;
•(4) KPS scores > 60;
•(5) Patients aged from 18 to 70 years;
•(6) Patients with life expectancy of at least 6 months;
•(7) Patients who provide written informed consent to participate in the study according to the GCP criteria.

•(1) Patients with metastatic gastric cancer;
•(2) Patients with histologically or imaging examination confirmed local recurrence or distant metastasis;
•(3) Patients who are pregnant, nursing;
•(4) Patients with severe primary cardiovascular disease, liver disease, kidney disease, blood disease or other diseases affecting survival;
•(5) Patients with disabilities are prescribed by law, including the blind, the deaf, dysgnosia, mental disturbance and extremity disability;
•(6) Patients who are alcohol dependence or substance abuse;
•(7) Patients with situations that reduce the possibility of enrollment or complicate the enrollment, such as frequent changes in working environment;
•(8) Patients who are allergic constitution,such as those who are allergic to more than 2 drugs and food, or those who are allergic to the ingredients of Jianpi Huayu Jiedu decoction;
•(9) Patients who are participating in the other clinical trials.

发起方

Jiangsu Province Hospital of Chinese Medicine